Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-19-0412
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy

Mayo Clinic Proceedings
Medicine
2019English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine
Oncology
2017English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

The Alveolar Immune Cell Landscape Is Dysregulated in Checkpoint Inhibitor Pneumonitis

Journal of Clinical Investigation
Medicine
2019English

Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges

Immunotherapy
OncologyAllergyImmunology
2016English

Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Clinical Cancer Research
Cancer ResearchOncology
2017English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy